Baseline characteristics of NAVIGATOR participants
| Variable | Included in analysis (n=2811) | Excluded from analysis (n=6495) |
|---|---|---|
| Age | 63 (58–68) | 63 (58–69) |
| Gender (female, %) | 1418 (50.4) | 3293 (50.7) |
| Race | ||
| Caucasian | 2243 (79.8) | 5491 (84.5) |
| Asian | 308 (11.0) | 305 (4.7) |
| African–American | 29 (1.0) | 207 (3.2) |
| Other | 231 (8.2) | 492 (7.6) |
| Weight (kg) | 80 (70–91) | 83 (72–95) |
| Systolic BP (mm Hg) | 140 (129–150) | 139 (128–150) |
| Coronary heart disease | 835 (29.7) | 1791 (27.6) |
| Cerebrovascular disease | 259 (9.2) | 477 (7.3) |
| Congestive heart failure | 124 (4.4) | 207 (3.2) |
| Peripheral arterial disease | 70 (2.5) | 239 (3.7) |
| Chronic obstructive pulmonary disease | 114 (4.1) | 337 (5.2) |
Values are median (IQR) or n (%).
BP, blood pressure; NAVIGATOR, Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research.